Autonomix Medical presents data showing 66% pain reduction at three months in pancreatic cancer study
AMIX•Autonomix Medical reported a 65.6% pain-score reduction at three months among six assessed responders in its initial proof-of-concept study; all seven responders assessed for opioid use required none. The company reported approximately $8.6 million in cash as of November 20, 2026, and targets FDA De Novo approval in 2028.
1. Study results and plans
Autonomix Medical reported a 65.6% pain-score reduction at three months among six responders assessed in its initial proof-of-concept study. All seven responders assessed for opioid use at three months required no opioids. The company said it had approximately $8.6 million in cash as of November 20, 2026, funding operations into, but not beyond, the third quarter of 2027, and targets FDA De Novo approval in 2028 for pancreatic cancer-related pain. A follow-on, 20-subject study evaluates its sensing and ablation catheters in additional visceral cancers and earlier-stage pancreatic cancer.




